VolitionRx Secures $2.0 Million in Funding
Stocks in this Quantisnow insightHealth Care
Historical context for VNRX
Across the 8 sessions after earlier VNRX headlines, the stock closed higher 5 times and lower 3 times, with a median move of 8.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VNRX | SPY |
|---|---|---|---|
| Jan 8, 2026 | VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats | +24.2% | -0.0% |
| Dec 17, 2025 | Volition Issues Business Review 2025 | +10.3% | -1.1% |
| Dec 11, 2025 | Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment | +2.6% | +0.2% |
| Dec 8, 2025 | Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer | -0.7% | -0.3% |
| Dec 4, 2025 | VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis | +9.5% | +0.1% |
| Nov 25, 2025 | VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use | -10.0% | +0.9% |
Quantisnow market dataAMEX
VNRX
VolitionRX Limited
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Listed since
- 2015
Get push alerts for VNRX
Full VNRX profile on Quantisnow Follow VNRX and get a push notification the moment its next story breaks.